5 Best Dialysis and Kidney Disease Stocks to Buy

2. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holders In Q2 2023: 78

Market Capitalization: $266.1 Billion

New Jersey-based Merck & Co., Inc. (NYSE:MRK) was founded in 1891. It has been offering comprehensive medical plans and services since then globally. With a market capitalization of whopping $266 billion, Merck & Co., Inc. (NYSE:MRK) ranks 2nd in our list of the best dialysis and kidney disease stocks to buy. It received a fast track designation from the US Food and Drug Administration for the company’s investigational anticoagulant therapy MK-2060 to mitigate risk of thrombotic cardiovascular events in patients suffering from end-stage renal disease. Merck & Co., Inc. (NYSE:MRK) posted total revenue of $15 billion in Q2, that grew 14%.

As of June 2023, 78 out of the 910 hedge funds part of Insider Monkey’s database were Merck & Co., Inc. (NYSE:MRK)’s investors. The largest shareholder was AQR Capital Management in our database with its $331.8 million investment.